UK markets closed
  • FTSE 100

    7,168.65
    -0.63 (-0.01%)
     
  • FTSE 250

    18,636.98
    -29.80 (-0.16%)
     
  • AIM

    875.21
    -1.01 (-0.12%)
     
  • GBP/EUR

    1.1593
    -0.0018 (-0.16%)
     
  • GBP/USD

    1.2103
    -0.0072 (-0.59%)
     
  • BTC-GBP

    15,841.73
    -478.07 (-2.93%)
     
  • CMC Crypto 200

    420.84
    +0.70 (+0.17%)
     
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • DOW

    31,097.26
    +321.83 (+1.05%)
     
  • CRUDE OIL

    108.46
    +2.70 (+2.55%)
     
  • GOLD FUTURES

    1,812.90
    +5.60 (+0.31%)
     
  • NIKKEI 225

    25,935.62
    -457.42 (-1.73%)
     
  • HANG SENG

    21,859.79
    -137.10 (-0.62%)
     
  • DAX

    12,813.03
    +29.26 (+0.23%)
     
  • CAC 40

    5,931.06
    +8.20 (+0.14%)
     

Global Cell Surface Markers Market to Reach $1 Billion by 2026

·28-min read
ReportLinker
ReportLinker

Abstract: What`s New for 2022? -Global competitiveness and key competitor percentage market shares. -Market presence across multiple geographies - Strong/Active/Niche/Trivial.

New York, June 16, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cell Surface Markers Industry" - https://www.reportlinker.com/p05818177/?utm_source=GNW
-Online interactive peer-to-peer collaborative bespoke updates
-Access to our digital archives and MarketGlass Research Platform
-Complimentary updates for one year

Global Cell Surface Markers Market to Reach $1 Billion by 2026

Cell surface markers or cell surface antigens are special carbohydrates or proteins present on cell membrane and can be exploited for identification and classification of cells. A growing number of healthcare facilities including hospitals, doctor`s offices, and diagnostic centers, as well as research entities including pharmaceutical laboratories, independent research institutions, academic/university research programs, and contract research organizations are prioritizing cell surface markers identification in diagnosis as well as research applications. Growth in the global market is set to be fueled by increasing adoption of sophisticated analytical technologies and in-vitro diagnostic tools as a result of ongoing efforts to reduce disease and to reduce healthcare burden. The market is also benefitting from rising application of stem cell technology, and efforts to reduce disease diagnosis costs. The emergence of new therapies to target liver cancer stem cells is expected to improve overall efficacy of traditional radiotherapy and chemotherapy procedures intended to treat liver cancer. One of the noteworthy developments in this direction is the identification of an ATP-competitive mTOR inhibitor, INK128, which holds potential to suppress CD44+, a liver cancer stem cell surface marker, along with sorafenib-insensitive hepatocellular carcinoma in-vivo and in-vitro.

Amid the COVID-19 crisis, the global market for Cell Surface Markers estimated at US$615.4 Million in the year 2020, is projected to reach a revised size of US$1 Billion by 2026, growing at a CAGR of 8.9% over the analysis period. Antibodies, one of the segments analyzed in the report, is projected to grow at a 10.7% CAGR to reach US$703.8 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the PCR Arrays segment is readjusted to a revised 6.4% CAGR for the next 7-year period. This segment currently accounts for a 43.8% share of the global Cell Surface Markers market.

The U.S. Market is Estimated at $315.3 Million in 2021, While China is Forecast to Reach $85.5 Million by 2026

The Cell Surface Markers market in the U.S. is estimated at US$315.3 Million in the year 2021. The country currently accounts for a 45.37% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$85.5 Million in the year 2026 trailing a CAGR of 10.8% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.4% and 8.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.9% CAGR while Rest of European market (as defined in the study) will reach US$93.8 Million by the end of the analysis period. Growth in North America region is attributed to the presence of prominent players, strong focus on R&D and extensive customer base. The regional market growth is augmented by rising use of cell surface markers in personalized medicine and drug discovery. The market growth is also facilitated by rising cases of chronic medical conditions, mainly cancer, and the resulting requirement of effective diagnostic capabilities. Growing healthcare and research expenditure, increased uptake of medical devices, and move towards laboratory automation are the major growth drivers fueling market expansion in developing regions.
Select Competitors (Total 70 Featured) -

  • Abbott Laboratories, Inc.

  • BD Biosciences

  • Beckman Coulter, Inc.

  • Bio-Rad Laboratories, Inc.

  • F. Hoffmann-La Roche AG

  • Grifols, S.A.

  • Immucor, Inc.

  • Nihon Kohden Corporation

  • Siemens Healthineers AG

  • Sysmex Corporation

  • Thermo Fisher Scientific Inc.




Read the full report: https://www.reportlinker.com/p05818177/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Cell Surface Markers: A Prelude
Researchers Indentify Over-Expression of CD8 Marker on
Cytotoxic T-Cells in Patients with COVID-19 Infection
Cell Surface Markers - Global Key Competitors Percentage Market
Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Hospitals Eye on CRP as Diagnostic Marker to Distinguish Common
Cold from COVID-19
Robust Demand for Analytical Techniques and Focus on Timely
Diagnosis Drive Growth of Global Cell Surface Markers Market
Research Dominates Cell Surface Markers Market, Clinical
Diagnostics to Exhibit Fastest Growth
Flow Cytometers Lead the Cell Surface Markers Market
T and B Cells Dominate the Market
Developed Regions: Major Revenue Contributors
Developing Regions Drive Future Growth
Recent Market Activity
Innovations & Advancements

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
High Uptake in Drug Discovery Applications Widens Market Prospects
Role of Flow Cytometry in Cell Line Development
Multicolor Flow Cytometry Offers Perfect Option to Understand
B-Cell Development
Hematology Analyzers Gain Traction in Cell Surface Marker
Identification
Growing Hematology Analyzers Market Witnesses Steady Growth
Key Technology Trends in Hematology Analyzers Market
Rising Cancer Incidence Worldwide Spurs Demand For Cell Surface
Markers
Select Markers for Cancer Stem Cell Identification
Global Cancer Incidence: Number of New Cancer Cases in Million
for the Years 2018, 2020, 2025, 2030, 2035 and 2040
Global Number of New Cancer Cases and Cancer-related Deaths by
Cancer Site for 2018
Number of New Cancer Cases and Deaths (in Million) by Region
for 2018
Use of CD Markers in Identification and Classification of
Leukocyte Populations
Most Common CD markers for Flow Cytometry
Growing Significance of Personalized Medicine: An Opportunity
for Cell Surface Markers
Global Personalized Medicine Market: Revenues in US$ Million
for the Years 2019 and 2024
RNA Sequencing Emerges as Potential Approach to Identify Cell
Surface Markers for Enabling Precision Medicine
Cell Surface Markers Grows Significantly in Stem Cell Research
Select Cell Surface Markers Used in Stem Cell Identification
and Characterization
Hematopoietic Stem Cell Markers Provide Useful Insights into
Hematopoiesis
Genetically Engineered CAR T-Cells Present Potential Weapon to
Eliminate Cancer Stem Cells and Prevent Recurrence of Cancer
Key Models
CSC Population & Noteworthy Markers
ALDH
CD44
CD90
CD133
EpCAM & EGFR
Immunotherapy Targets Natural Killer Cells to Offer Hope for
Cancer Patients
Cell Surface Markers Identification Assumes Critical Importance
amid Growing Prevalence of Chronic Diseases
Fatalities by Heart Conditions: Estimated Percentage Breakdown
for Cardiovascular Disease, Ischemic Heart Disease, Stroke,
and Others
Rising Diabetes Prevalence Presents Opportunity for Cell
Surface Markers: Number of Adults (20-79) with Diabetes
(in Millions) by Region for 2017 and 2045
Aging Demographics Present Opportunities for Cell Surface Markers
Expanding Elderly Population Worldwide: Breakdown of Number of
People Aged 65+ Years in Million by Geographic Region for the
Years 2019 and 2030
Clinical Management of Autoimmune Diseases
Flow Cytometry Remains the Gold Standard in HIV Testing and
Monitoring
Global HIV Prevalence: 2019
Increased Emphasis on Lab Automation Builds Opportunities
Increasing Investments on Advanced Equipment in Disease
Diagnosis Underpin Volume Growth
Growing Focus on Data Management in Research Programs Extends
Opportunities
Rat Markers
Lineage and Antibodies Specific Rat Markers
Commonly Used Key Rat Markers by Antibodies and Research Area/
Target Cell
New Anti-Rat Antibodies Products Expand Scope of Applications
ED Clone Anti-Rat Antibodies by Marker and Cell Type
Rat Flow Cytometry Panels

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for Cell
Surface Markers by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Cell Surface Markers by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Cell Surface Markers by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis for
Antibodies by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Antibodies by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Antibodies by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for PCR
Arrays by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for PCR Arrays by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for PCR Arrays by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis for T
Cell by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for T Cell by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for T Cell by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis for B
Cell by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for B Cell by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for B Cell by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis for NK
Cell by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for NK Cell by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 18: World 15-Year Perspective for NK Cell by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 19: World Recent Past, Current & Future Analysis for
Monocyte Cell by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Monocyte Cell by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Monocyte Cell by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 22: World Recent Past, Current & Future Analysis for
Other Cell Types by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Other Cell Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Other Cell Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 25: World Recent Past, Current & Future Analysis for
Research by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Research by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 27: World 15-Year Perspective for Research by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 28: World Recent Past, Current & Future Analysis for
Clinical by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Clinical by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 30: World 15-Year Perspective for Clinical by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 31: World Recent Past, Current & Future Analysis for
Academic & Research Institutes by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Academic & Research
Institutes by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Academic & Research
Institutes by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2021 &
2027

Table 34: World Recent Past, Current & Future Analysis for
Hospitals & Clinical Laboratories by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 35: World Historic Review for Hospitals & Clinical
Laboratories by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 36: World 15-Year Perspective for Hospitals & Clinical
Laboratories by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2021 & 2027

Table 37: World Recent Past, Current & Future Analysis for
Other End-Uses by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 38: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 39: World 15-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Largest Market for Cell Surface Markers
Rising Cancer Cases Spur Growth in Cell Surface Markers Market
Estimated Number of New Cancer Cases and Deaths in the US (2019)
Number of Cancer Drugs in Development for the Years 2006, 2009,
2012, 2015 and 2018
Market Benefits from Growing Funding for Stem Cell Research
Stem Cell Research Funding in the US (in US$ Million) for the
Years 2011 through 2017
Cell Surface Markers Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2022 (E)
Table 40: USA Recent Past, Current & Future Analysis for Cell
Surface Markers by Product - Antibodies and PCR Arrays -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Cell Surface Markers by
Product - Antibodies and PCR Arrays Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 42: USA 15-Year Perspective for Cell Surface Markers by
Product - Percentage Breakdown of Value Sales for Antibodies
and PCR Arrays for the Years 2012, 2021 & 2027

Table 43: USA Recent Past, Current & Future Analysis for Cell
Surface Markers by Cell Type - T Cell, B Cell, NK Cell,
Monocyte Cell and Other Cell Types - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 44: USA Historic Review for Cell Surface Markers by Cell
Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell
Types Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 45: USA 15-Year Perspective for Cell Surface Markers by
Cell Type - Percentage Breakdown of Value Sales for T Cell, B
Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years
2012, 2021 & 2027

Table 46: USA Recent Past, Current & Future Analysis for Cell
Surface Markers by Application - Research and Clinical -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 47: USA Historic Review for Cell Surface Markers by
Application - Research and Clinical Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 48: USA 15-Year Perspective for Cell Surface Markers by
Application - Percentage Breakdown of Value Sales for Research
and Clinical for the Years 2012, 2021 & 2027

Table 49: USA Recent Past, Current & Future Analysis for Cell
Surface Markers by End-Use - Academic & Research Institutes,
Hospitals & Clinical Laboratories and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 50: USA Historic Review for Cell Surface Markers by
End-Use - Academic & Research Institutes, Hospitals & Clinical
Laboratories and Other End-Uses Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 51: USA 15-Year Perspective for Cell Surface Markers by
End-Use - Percentage Breakdown of Value Sales for Academic &
Research Institutes, Hospitals & Clinical Laboratories and
Other End-Uses for the Years 2012, 2021 & 2027

CANADA
High Focus on Improving Healthcare Augurs Well for Market Growth
Number of New Cancer Cases in Canada: 2019
Table 52: Canada Recent Past, Current & Future Analysis for
Cell Surface Markers by Product - Antibodies and PCR Arrays -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 53: Canada Historic Review for Cell Surface Markers by
Product - Antibodies and PCR Arrays Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 54: Canada 15-Year Perspective for Cell Surface Markers
by Product - Percentage Breakdown of Value Sales for Antibodies
and PCR Arrays for the Years 2012, 2021 & 2027

Table 55: Canada Recent Past, Current & Future Analysis for
Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell,
Monocyte Cell and Other Cell Types - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 56: Canada Historic Review for Cell Surface Markers by
Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other
Cell Types Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 57: Canada 15-Year Perspective for Cell Surface Markers
by Cell Type - Percentage Breakdown of Value Sales for T Cell,
B Cell, NK Cell, Monocyte Cell and Other Cell Types for the
Years 2012, 2021 & 2027

Table 58: Canada Recent Past, Current & Future Analysis for
Cell Surface Markers by Application - Research and Clinical -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 59: Canada Historic Review for Cell Surface Markers by
Application - Research and Clinical Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 60: Canada 15-Year Perspective for Cell Surface Markers
by Application - Percentage Breakdown of Value Sales for
Research and Clinical for the Years 2012, 2021 & 2027

Table 61: Canada Recent Past, Current & Future Analysis for
Cell Surface Markers by End-Use - Academic & Research
Institutes, Hospitals & Clinical Laboratories and Other
End-Uses - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 62: Canada Historic Review for Cell Surface Markers by
End-Use - Academic & Research Institutes, Hospitals & Clinical
Laboratories and Other End-Uses Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 63: Canada 15-Year Perspective for Cell Surface Markers
by End-Use - Percentage Breakdown of Value Sales for Academic &
Research Institutes, Hospitals & Clinical Laboratories and
Other End-Uses for the Years 2012, 2021 & 2027

JAPAN
Cell Surface Markers Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2022 (E)
Table 64: Japan Recent Past, Current & Future Analysis for Cell
Surface Markers by Product - Antibodies and PCR Arrays -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 65: Japan Historic Review for Cell Surface Markers by
Product - Antibodies and PCR Arrays Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 66: Japan 15-Year Perspective for Cell Surface Markers by
Product - Percentage Breakdown of Value Sales for Antibodies
and PCR Arrays for the Years 2012, 2021 & 2027

Table 67: Japan Recent Past, Current & Future Analysis for Cell
Surface Markers by Cell Type - T Cell, B Cell, NK Cell,
Monocyte Cell and Other Cell Types - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 68: Japan Historic Review for Cell Surface Markers by
Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other
Cell Types Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 69: Japan 15-Year Perspective for Cell Surface Markers by
Cell Type - Percentage Breakdown of Value Sales for T Cell, B
Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years
2012, 2021 & 2027

Table 70: Japan Recent Past, Current & Future Analysis for Cell
Surface Markers by Application - Research and Clinical -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 71: Japan Historic Review for Cell Surface Markers by
Application - Research and Clinical Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 72: Japan 15-Year Perspective for Cell Surface Markers by
Application - Percentage Breakdown of Value Sales for Research
and Clinical for the Years 2012, 2021 & 2027

Table 73: Japan Recent Past, Current & Future Analysis for Cell
Surface Markers by End-Use - Academic & Research Institutes,
Hospitals & Clinical Laboratories and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 74: Japan Historic Review for Cell Surface Markers by
End-Use - Academic & Research Institutes, Hospitals & Clinical
Laboratories and Other End-Uses Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 75: Japan 15-Year Perspective for Cell Surface Markers by
End-Use - Percentage Breakdown of Value Sales for Academic &
Research Institutes, Hospitals & Clinical Laboratories and
Other End-Uses for the Years 2012, 2021 & 2027

CHINA
Increasing Cancer Research to Drive Cell Surface Markers Market
Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018
Cell Surface Markers Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2022 (E)
Table 76: China Recent Past, Current & Future Analysis for Cell
Surface Markers by Product - Antibodies and PCR Arrays -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 77: China Historic Review for Cell Surface Markers by
Product - Antibodies and PCR Arrays Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 78: China 15-Year Perspective for Cell Surface Markers by
Product - Percentage Breakdown of Value Sales for Antibodies
and PCR Arrays for the Years 2012, 2021 & 2027

Table 79: China Recent Past, Current & Future Analysis for Cell
Surface Markers by Cell Type - T Cell, B Cell, NK Cell,
Monocyte Cell and Other Cell Types - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 80: China Historic Review for Cell Surface Markers by
Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other
Cell Types Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 81: China 15-Year Perspective for Cell Surface Markers by
Cell Type - Percentage Breakdown of Value Sales for T Cell, B
Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years
2012, 2021 & 2027

Table 82: China Recent Past, Current & Future Analysis for Cell
Surface Markers by Application - Research and Clinical -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 83: China Historic Review for Cell Surface Markers by
Application - Research and Clinical Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 84: China 15-Year Perspective for Cell Surface Markers by
Application - Percentage Breakdown of Value Sales for Research
and Clinical for the Years 2012, 2021 & 2027

Table 85: China Recent Past, Current & Future Analysis for Cell
Surface Markers by End-Use - Academic & Research Institutes,
Hospitals & Clinical Laboratories and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 86: China Historic Review for Cell Surface Markers by
End-Use - Academic & Research Institutes, Hospitals & Clinical
Laboratories and Other End-Uses Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 87: China 15-Year Perspective for Cell Surface Markers by
End-Use - Percentage Breakdown of Value Sales for Academic &
Research Institutes, Hospitals & Clinical Laboratories and
Other End-Uses for the Years 2012, 2021 & 2027

EUROPE
Cell Surface Markers Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2022 (E)
Cancer Incidence in Europe: Number of New Cancer Cases
(in Thousands) by Site for 2018
Table 88: Europe Recent Past, Current & Future Analysis for
Cell Surface Markers by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 89: Europe Historic Review for Cell Surface Markers by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 90: Europe 15-Year Perspective for Cell Surface Markers
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2021 & 2027

Table 91: Europe Recent Past, Current & Future Analysis for
Cell Surface Markers by Product - Antibodies and PCR Arrays -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 92: Europe Historic Review for Cell Surface Markers by
Product - Antibodies and PCR Arrays Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 93: Europe 15-Year Perspective for Cell Surface Markers
by Product - Percentage Breakdown of Value Sales for Antibodies
and PCR Arrays for the Years 2012, 2021 & 2027

Table 94: Europe Recent Past, Current & Future Analysis for
Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell,
Monocyte Cell and Other Cell Types - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 95: Europe Historic Review for Cell Surface Markers by
Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other
Cell Types Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 96: Europe 15-Year Perspective for Cell Surface Markers
by Cell Type - Percentage Breakdown of Value Sales for T Cell,
B Cell, NK Cell, Monocyte Cell and Other Cell Types for the
Years 2012, 2021 & 2027

Table 97: Europe Recent Past, Current & Future Analysis for
Cell Surface Markers by Application - Research and Clinical -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 98: Europe Historic Review for Cell Surface Markers by
Application - Research and Clinical Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 99: Europe 15-Year Perspective for Cell Surface Markers
by Application - Percentage Breakdown of Value Sales for
Research and Clinical for the Years 2012, 2021 & 2027

Table 100: Europe Recent Past, Current & Future Analysis for
Cell Surface Markers by End-Use - Academic & Research
Institutes, Hospitals & Clinical Laboratories and Other
End-Uses - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 101: Europe Historic Review for Cell Surface Markers by
End-Use - Academic & Research Institutes, Hospitals & Clinical
Laboratories and Other End-Uses Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 102: Europe 15-Year Perspective for Cell Surface Markers
by End-Use - Percentage Breakdown of Value Sales for Academic &
Research Institutes, Hospitals & Clinical Laboratories and
Other End-Uses for the Years 2012, 2021 & 2027

FRANCE
Cell Surface Markers Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2022 (E)
Table 103: France Recent Past, Current & Future Analysis for
Cell Surface Markers by Product - Antibodies and PCR Arrays -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 104: France Historic Review for Cell Surface Markers by
Product - Antibodies and PCR Arrays Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 105: France 15-Year Perspective for Cell Surface Markers
by Product - Percentage Breakdown of Value Sales for Antibodies
and PCR Arrays for the Years 2012, 2021 & 2027

Table 106: France Recent Past, Current & Future Analysis for
Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell,
Monocyte Cell and Other Cell Types - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 107: France Historic Review for Cell Surface Markers by
Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other
Cell Types Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 108: France 15-Year Perspective for Cell Surface Markers
by Cell Type - Percentage Breakdown of Value Sales for T Cell,
B Cell, NK Cell, Monocyte Cell and Other Cell Types for the
Years 2012, 2021 & 2027

Table 109: France Recent Past, Current & Future Analysis for
Cell Surface Markers by Application - Research and Clinical -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 110: France Historic Review for Cell Surface Markers by
Application - Research and Clinical Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 111: France 15-Year Perspective for Cell Surface Markers
by Application - Percentage Breakdown of Value Sales for
Research and Clinical for the Years 2012, 2021 & 2027

Table 112: France Recent Past, Current & Future Analysis for
Cell Surface Markers by End-Use - Academic & Research
Institutes, Hospitals & Clinical Laboratories and Other

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05818177/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting